Efficacy and tolerability of prostaglandin-timolol fixed combinations: A meta-analysis of randomized clinical trials

European Journal of Ophthalmology

Volumn 22, Issue 1, 2011, Pages 5-18

  Aptel, Florent ^a   Cucherat, Michel ^b   Denis, Philippe ^c  

^a EDOUARD HERRIOT HOSPITAL   (France)

^b UNIVERSITÉ LYON 1   (France)

^c CROIX ROUSSE HOSPITAL   (France)

Author keywords

Effect size; Fixed combination; Glaucoma; Intraocular pressure; Meta analysis; Prosta glandin timolol

Indexed keywords

ANTIGLAUCOMA AGENT; BIMATOPROST; BIMATOPROST PLUS TIMOLOL; LATANOPROST; LATANOPROST PLUS TIMOLOL; PROSTAGLANDIN; PROSTAGLANDIN PLUS TIMOLOL; TIMOLOL PLUS TRAVOPROST; TRAVOPROST; UNCLASSIFIED DRUG;

ADULT; ARTICLE; CONJUNCTIVAL HYPEREMIA; CONTROLLED STUDY; DOSAGE SCHEDULE COMPARISON; DRUG ACTIVITY; DRUG EFFICACY; DRUG TOLERABILITY; EVENING DOSAGE; FEMALE; FOLLOW UP; GLAUCOMA; HUMAN; INTRAOCULAR HYPERTENSION; INTRAOCULAR PRESSURE; INTRAOCULAR PRESSURE LOWERING EFFECT; MAJOR CLINICAL STUDY; MALE; META ANALYSIS; MONOTHERAPY; MORNING DOSAGE; PATIENT COMPLIANCE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); SYSTEMATIC REVIEW;

AMIDES; ANTIHYPERTENSIVE AGENTS; CIRCADIAN RHYTHM; CLOPROSTENOL; DRUG COMBINATIONS; GLAUCOMA; HUMANS; HYPEREMIA; INTRAOCULAR PRESSURE; PROSTAGLANDINS F, SYNTHETIC; RANDOMIZED CONTROLLED TRIALS AS TOPIC; TIMOLOL; TREATMENT OUTCOME;

EID: 81855166777     PISSN: 11206721     EISSN: None     Source Type: Journal    
DOI: 10.5301/ejo.5000009     Document Type: Article

References (41)

1. Weinreb RN, Khaw PT. Primary open-angle glaucoma. Lancet 2004; 363: 1711-20.
2. Kass MA, Heuer DK, Higginbotham EJ, et al. The Ocular Hypertension Treatment Study: a randomized trial determines that topical ocular hypotensive medication delays or prevents the onset of primary open-angle glaucoma. Arch Ophthalmol 2002; 120: 701-13.
3. Baudouin C, Labbé A, Liang H, Pauly A, Brignole-Baudouin F. Preservatives in eyedrops: the good, the bad and the ugly. Prog Retin Eye Res 2010; 29: 312-34.
4. Robin AL, Novack GD, Covert DW, Crockett RS, Marcic TS. Adherence in glaucoma: objective measurements of once-daily and adjunctive medication use. Am J Ophthalmol 2007; 144: 533-40.
5. Covert D, Robin AL. Adjunctive glaucoma therapy use associated with travoprost, bimatoprost, and latanoprost. Curr Med Res Opin 2006; 22: 971-6.
6. Terminology and Guidelines for Glaucoma (European Guidelines), 3rd ed. Savona: DOGMA, 2008; 86-104.
7. Weinreb RN, Liebmann J. Medical Treatment of Glaucoma. Amsterdam: Kugler Publications, 2010; 117-169.
8. Martinez A, Sanchez M. Bimatoprost/timolol fixed combination vs latanoprost/timolol fixed combination in open-angle glaucoma patients. Eye 2009; 23: 810-8.
9. Centofanti M, Oddone F, Vetrugno M, et al. Efficacy of the fixed combinations of bimatoprost or latanoprost plus timolol in patients uncontrolled with prostaglandin monotherapy: a multi-center, randomized, investigator-masked, clinical study. Eur J Ophthalmol 2009; 19: 66-71.
10. Martinez A, Sanchez M. A comparison of the safety and intraocular pressure lowering of bimatoprost/timolol fixed combination versus latanoprost/timolol fixed combination in patients with open-angle glaucoma. Curr Med Res Opin 2007; 23: 1025-32.
11. Topouzis F, Melamed S, Danesh-Meyer H, et al. A 1-year study to compare the efficacy and safety of once-daily travoprost 0.004%/timolol 0.5% to once-daily latanoprost 0.005%/timolol 0.5% in patients with open-angle glaucoma or ocular hypertension. Eur J Ophthalmol 2007; 17: 183-90.
12. Centofanti M, Oddone F, Gandolfi S, et al. Comparison of tra-voprost and bimatoprost plus timolol fixed combinations in open-angle glaucoma patients previously treated with latano-prost plus timolol fixed combination. Am J Ophthalmol 2010; 150: 575-80.
13. Brandt JD, Cantor LB, Katz LJ, Batoosingh AL, Chou C, Bossowska I, Ganfort Investigators Group II. Bimatoprost/ timolol fixed combination: a 3-month double-masked, randomized parallel comparison to its individual components in patients with glaucoma or ocular hypertension. J Glaucoma 2008; 17: 211-6.
14. Hommer A, Ganfort Investigators Group I. A double-masked, randomized, parallel comparison of a fixed combination of bi-matoprost 0.03%/timolol 0.5% with non-fixed combination use in patients with glaucoma or ocular hypertension. Eur J Oph-thalmol 2007; 17: 53-62.
15. Palmberg P, Kim EE, Kwok KK, Tressler CS, Canada and United States Fixed Combination Latanoprost/Timolol Study Group. A 12-week, randomized, double-masked study of fixed combination latanoprost/timolol versus latanoprost or timolol mono-therapy. Eur J Ophthalmol 2010; 20: 708-18.
16. Higginbotham EJ, Olander KW, Kim EE, Grunden JW, Kwok KK, Tressler CS, United States Fixed-Combination Study Group. Fixed combination of latanoprost and timolol vs individual components for primary open-angle glaucoma or ocular hypertension: a randomized, double-masked study. Arch Oph-thalmol 2010; 128: 165-72.
17. Magacho L, Reis R, Shetty RK, Santos LC, Avila M P. Efficacy of latanoprost or fixed-combination latanoprost-timolol in patients switched from a combination of timolol and a nonprostaglandin medication. Ophthalmology 2006; 113: 442-4.
18. Konstas AG, Boboridis K, Tzetzi D, Kallinderis K, Jenkins JN, Stewart WC. Twenty-four-hour control with latanoprost-timolol-fixed combination therapy vs latanoprost therapy. Arch Oph-thalmol 2005; 123: 898-902.
19. Olander K, Zimmerman TJ, Downes N, Schoenfelder J, Xala-com/Latanoprost Study Group. Switching from latanoprost to fixed-combination latanoprost-timolol: a 21-day, randomized, double-masked, active-control study in patients with glaucoma and ocular hypertension. Clin Ther 2004; 26: 1619-29.
20. Higginbotham EJ, Feldman R, Stiles M, Dubiner H, Fixed Combination Investigative Group. Latanoprost and timolol combination therapy vs monotherapy: one-year randomized trial. Arch Ophthalmol 2002; 120: 915-22.
21. Pfeiffer N, European Latanoprost Fixed Combination Study Group. A comparison of the fixed combination of latanoprost and timolol with its individual components. Graefes Arch Clin Exp Ophthalmol 2002; 240: 893-9.
22. Diestelhorst M, Almegård B. Comparison of two fixed combinations of latanoprost and timolol in open-angle glaucoma. Graefes Arch Clin Exp Ophthalmol 1998; 236: 577-81.
23. Konstas AG, Pikilidou MI, Tsironi S, et al. 24-hour intraocular pressure and blood pressure levels with latanoprost/timolol fixed combination versus timolol. Curr Eye Res 2009; 34: 369-77.
24. Konstas AG, Lake S, Economou AI, Kaltsos K, Jenkins JN, Stewart WC. 24-Hour control with a latanoprost-timolol fixed combination vs timolol alone. Arch Ophthalmol 2006; 124: 1553-7.
25. Konstas AG, Mikropoulos D, Haidich AB, Ntampos KS, Stewart WC. Twenty-four-hour intraocular pressure control with the travoprost/timolol maleate fixed combination compared with travoprost when both are dosed in the evening in primary open-angle glaucoma. Br J Ophthalmol 2009; 93: 481-5.
26. Barnebey HS, Orengo-Nania S, Flowers BE, et al. The safety and efficacy of travoprost 0.004%/timolol 0.5% fixed combination ophthalmic solution. Am J Ophthalmol 2005; 140: 1-7.
27. Schuman JS, Katz GJ, Lewis RA, et al. Efficacy and safety of a fixed combination of travoprost 0.004%/timolol 0.5% ophthalmic solution once daily for open-angle glaucoma or ocular hypertension. Am J Ophthalmol 2005; 140: 242-50.
28. Moher D, Liberati A, Tetzlaff J, Altman DG, PRISMA Group. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. BMJ 2009; 339: b2535.
29. Haynes RB, McKibbon KA, Wilczynski NL, Walter SD, Werre SR, Hedges Team. Optimal search strategies for retrieving scientifically strong studies of treatment from Medline: analytical survey. BMJ 2005; 330: 1179.
30. Jadad AR, Moore RA, Carroll D, et al. Assessing the quality of reports of randomized clinical trials: is blinding necessary? Control Clin Trials 1996; 17: 1-12.
31. Schulz KF, Altman DG, Moher D. Allocation concealment in clinical trials. JAMA 2002; 288: 2406-9.
32. Jüni P, Egger M. Allocation concealment in clinical trials. JAMA 2002; 288: 2407-9.
33. Follmann D, Elliott P, Suh I, Cutler J. Variance imputation for overviews of clinical trials with continuous response. J Clin Epidemiol 1992; 45: 769-73.
34. Olkin I. Statistical and theoretical considerations in meta-analysis. J Clin Epidemiol 1995; 48: 133-47.
35. Konstas AG, Mikropoulos DG, Embeslidis TA, et al. 24-h Intraocular pressure control with evening-dosed travoprost/ timolol, compared with latanoprost/timolol, fixed combinations in exfoliative glaucoma. Eye 2010; 24: 1606-13.
36. Tabet R, Stewart WC, Feldman R, Konstas AG. A review of additivity to prostaglandin analogs: fixed and unfixed combinations. Surv Ophthalmol 2008; 53(suppl 1): S85-92.
37. Higginbotham EJ. Considerations in glaucoma therapy: fixed combinations versus their component medications. Clin Ophthalmol 2010; 4: 1-9.
38. Webers CA, Beckers HJ, Zeegers M P, Nuijts RM, Hendrikse F, Schouten JS. The intraocular pressure-lowering effect of prostaglandin analogs combined with topical β-blocker therapy: a systematic review and meta-analysis. Ophthalmology 2010; 117: 2067-74.
39. Aptel F, Cucherat M, Denis P. Efficacy and tolerability of prostaglandin analogs: a meta-analysis of randomized controlled clinical trials. J Glaucoma 2008; 17: 667-73.
40. Quaranta L, Riva I, Russo A, et al. Prostaglandin analogues (PGAs) and timolol fixed combination (Fc) vs. extemporaneous combination (Ec) or monotherapy (Mt) in the treatment of primary open-angle glaucoma (POAG) and ocular hypertension (OHT): a systematic review and meta-analysis. Invest Ophthalmol Vis Sci 2011; 52: E-Abstract 215.
41. Konstas AG, Holló G, Mikropoulos D, et al. Twenty-four-hour intraocular pressure control with bimatoprost and the bimatoprost/timolol fixed combination administered in the morning, or evening in exfoliative glaucoma. Br J Ophthal-mol 2010; 94: 209-13.